CYCJET flying laser marking machine is not just an upgrade of marking tools, but a strategic investment for enterprises moving towards green and intelligent manufacturing. From reducing environmental footprint to improving production line efficiency, CYCJET helps global customers find the optimal balance between compliance, cost, and brand value.
XUN COUNTY, Henan Province, Feb 10 — Lanterns illuminated millennium-old walls Saturday evening as the 18th Central Plains (Hebi) Folk Culture Festival opened in Xun County, transforming this national historical city into a vibrant stage where ancient heritage meets modern celebration.
SURABAYA,Indonesia,Dec. 17,2024-- It is already that time of the year. As the holiday season approaches,families are eager to create lasting memories with festive vacations,including relaxing hotelsta
CULVER CITY,Calif.,Dec. 17,2024--Snail,Inc. (Nasdaq: SNAL) ("Snail Games" or the "Company"),a leading global independent developer and publisher of interactive digital entertainmen
BEIJING,Dec. 17,2024-- WiMi Hologram Cloud Inc. (NASDAQ: WiMi) ("WiMi" or the "Company"),a leading global Hologram Augmented Reality ("AR") Technology provider,today anno
STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn\'s disease (CD) and ulcerative coliti
SAMARKAND,Uzbekistan,Dec. 12,2024--On December 6,2024,the China National Silk Museum launched the third thematic exhibition "Silk and Silk Roads: From Hangzhou to Samarkand" at the Samarkand
SHENZHEN,China,Dec. 12,2024-- Saint-Gobain Group,a global leader in lightweight and sustainable construction solutions,reinvested in the Luohu district of Shenzhen this year.
12-18 Shenzhen Luohu District Publicity Department
XIAMEN,China,Dec. 13,2024--Lichen China Limited (Nasdaq: LICN)("Lichen China" or the "Company"),a dedicated financial and taxation service provider inChina today announced that it
SUZHOU,China,Dec. 13,2024-- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from a phase II clinical study on PD-L1/CTLA-4 bispecific antibody KN046 in combination with
